reason report
bottom line continu believ alexion stock
under-valued base excess concern competit
threat compani complement franchis
appreci compani life-cycl extens strategi
address concern updat model captur market
market indic indic transit ultomiri
biosimilar like enter produc
modest reduct revenu forecast still leav us consider
recent consensu importantli analysi suggest
alexion total revenu expos biosimilar
competit time first could launch
consist observ investor undervalu
full revenu potenti complex portfolio incorpor
substitut alexion outlook appear fall victim
under-forecast mani investor fear biosimilar
competit soliri earli analysi suggest
alexion total revenu base risk
biosimilar enter european market updat
explicitli forecast revenu soliri recent approv longer
act antibodi ultomiri four indic paroxysm
ahu myasthenia gravi mg neuromyel optica nmo
includ revenu indic enter
al primari progress multipl sclerosi ppm
incorpor opportun compani self-inject
subcutan sc dose formul ultomiri could come
market soon model transit revenu
soliri ultomiri success launch
well impact biosimilar entri major european market
get conflict advic valu orphan
drug exclus ode europ follow biosimilar launch non-
exclus indic conclud safest approach
assum benefit ode circumst biosimilar use
indic origin innov molecul assumpt
made less conserv biosimilar eros
confin like-for-lik substitut drug soliri rather
affect later gener drug well ultomiri
chang result reduct revenu declin
expect ep year forecast remain materi current
consensu revenu earn incorpor chang
arriv updat price target
alexion recent close price maintain
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
outperform rate alexion stock expect stock continu
appreci new indic new formul continu enhanc
valu compani complement franchis support continu
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi upcom label expans on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain
futur find alexion well posit grow ep doubl digit next five
ultomiri ravulizumab alexion longer half-lif version antibodi soliri eculizumab
approv initi indic pnh paroxysm nocturn hemoglobinuria late last year
ultomiri offer slightli better efficaci note conveni everi week dose
vs everi two week compar soliri eculizumab gener world-wide sale
recent alexion announc price ultomiri discount soliri
note estim pnh adult patient subsequ
indic ahu mg nmo agre compani strategi
design encourag switch newer product believ respons decis
alexion manag sinc franchis transit ultra-rar indic
patient us rare diseas popul patient rang
addit benefit switch strategi ultomiri would extend patent life
alexion complement franchis mid-lat durabl
revenu stream controversi topic among investor time alexion recent
guid achiev switch ultomiri major market us germani japan within
two year product launch ultomiri indic pnh ahu prior medacorp
survey work suggest achiev note
demis one competit risk seem gone unnot
surpris alexion stock benefit data present
roche/chugai last decemb long act antibodi
consid threaten potenti brand competitor soliris/ultomiri
previous receiv mani inquiri program last year saw first
present safeti efficaci result phase i/ii studi pnh patient
note present half-lif estim day subject
dose iv subcutan inject infrequ monthli compar
favor soliri everi week iv less attract compar day half-lif
everi week iv administr ultomiri may also becom avail
notabl disclosur incid serum sick reaction
subject switch soliri reaction result drug-
target-drug complex dtdc due fact bind differ epitop
protein soliri ultomiri reaction occur bind free
presenc soliri alreadi bound target protein thu form complex
believ caus advers event trial affect patient abl continu
treatment addit steroid regimen risk advers event ae
liabil would certainli limit adopt real world consid
pnh ahu commerci opportun driven chronic administr view
dtdc repres signific find becom even problemat
transit soliri ultomiri much longer half-lif could requir washout
period month least extend cours steroid facilit transit
base case assumpt orphan drug exclus protect soliri
europ orphan drug design grant period market exclus time
regulatori approv assum mp first biosimilar soliri enter market
could approv pnh indic given outstand exclus period
ahu nov mg nmo exhibit howev
separ jurisdict regulatori author european medicin agenc ema
government health agenc ultim decid local price launch mani
case access research suggest certain geographi biosimilar eculizumab could
use soliri indic regardless outstand ode protect like
view vari wide countri countri basi cost consciou countri
uk scandinavia allow broad use biosimilar eculizumab other may restrict use
initi label indic conserv model assum biosimilar
eculizumab approv market market eros soliri affect approv soliri
indic pnh
exhibit timelin soliri exclus period across geographi
newer indic doubl total number patient drug
alexion one success rare diseas franchis time refin concept
turn small underdiagnos seriou diseas blockbust indic charg high
price per-pati basi increas number orphan rare diseas medicin
approach market payer politician begin pay attent
overal per-pati drug expenditur system price power across industri
threat prior approv myasthenia gravi soliri two indic pnh ahu
amount elig patient unit state estim
patient maintain soliri approv mg increas elig treatment
popul model suggest expect nmo approv later year add
anoth elig patient essenc elig patient pool increas
us begin end exhibit alexion alreadi
rapidli penetr newli elig mg popul soliri expect similar
slightli slower adopt nmo begin later year forecast predict
total number patient soliris/ultomiri us doubl number given
materi expans address patient popul compani medicin
anticip reduct price time ultomiri posit price
entir consist strategi lower ultomiri price also pose challeng
biosimilar develop sinc primarili launch substitut soliri rather
ultomiri unclear whether launch price discount origin
region protectionexpirationusorphan drug exclus drug exclus drug exclus drug exclus drug exclus drug exclus drug exclus drug exclus drug exclus svb leerink research alexion compani file alexion inc
gener brand govern payer sinc eu approv possibl
respond like match price alexion soliri
exhibit total treat patient complement therapi doubl level
updat market model forecast peak ultomiri convers rate major market
pnh ahu us germani japan geographi model
year ramp peak convers case alexion guidanc within
first two year launch mg nmo peak penetr convers rate
lower due larger patient popul shorter length time indic specif
launch potenti entri biosimilar soliri product updat revenu forecast
model soliri ultomiri individu indic well geographi forecast
world-wide soliri revenu grow peak
ultomiri sale exceed soliri reach total forecast
alexion total complement franchis grow peak
exhibit driven mainli addit neuromuscular diseas indic exist
indic soliri repres alexion total revenu estim
combin soliris/ultomiri sale continu alexion total revenu mid-
exhibit total complement revenu grow
biosimilar eculizumab remain overhang revenu risk
biggest controversi long-term outlook alexion complement franchis remain
potenti revenu eros biosimilar eculizumab initi entri biosimilar version
soliri unlik occur prior europ commerci relev
part world per recent file alexion retain composit matter patent
protect soliri us japan europ howev
biosimilar develop could receiv european approv least two year
composit matter com expiri
amgen advanc biosimilar version soliri develop
knowledg recent initi phase studi outsid us estim amgen
biosimilar could enter european market soon secur approv pnh ode expir
estim around issu composit matter
formul patent soliri expir us japan prevent biosimilar entri
year
updat forecast revenu split product indic geographi estim
global soliri revenu year prior biosimilar launch toward
end year forecast approxim ww soliri sale europ
therefor potenti at-risk biosimilar eros equat alexion ww
soliri sale alexion total complement revenu alexion total product
revenu year exhibit
estim maximum downsid biosimilar eros europ
would alexion total revenu base assum soliri indic
immedi at-risk plausibl scenario like moder declin soliri
revenu europ multi-year period driven declin price brand soliri
respons competit bid biosimilar soliri like becom alexion fight brand
region period alway advantag refer product
mani thousand patient-year worth exposur unlik soliri disappear
altogeth believ like patient would forc switch brand
ultomiri biosimilar version soliri given efficaci conveni advantag
exhibit estim revenu breakdown time initi biosimilar entri eu
model updat reflect chang bring pt op
made extens updat market model compani model alexion
revis price target major chang revenu forecast rapid
uptak biosimilar eculizumab europ begin formal transit soliri
ultomiri market market indic indic basi incorpor current
ultomiri price indic geographi addit mg nmo indic
ultomiri total complement revenu forecast decreas low mid singl digit
percentag begin end forecast period due primarili
discount price associ convers soliri ultomiri expect adopt
biosimilar product mid-lat us complement forecast decreas
year due primarili rapid adopt curv ultomiri
next year pnh ahu outsid us near-term total complement
forecast increas singl digit percentag base launch trajectori soliri mg
nmo around world forecast peak soliri revenu peak
ultomiri revenu approach late estim includ ultomiri
convers rate us/germany/japan non-cor market
pnh ahu adjust forecast strensiq kanuma
alexion pipelin asset model warm autoimmun hemolyt anemia
waiha pemphigu vulgari pv result chang hold expens
constant total revenu forecast decreas low singl digit percentag futur year
pro forma dilut ep forecast also decreas
total revenu forecast remain recent consensu ep forecast
revis price target compar previous continu
see substanti upsid alexion stock near long term base improv
understand life-cycl manag strategi biosimilar competit landscap
outsid us
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use termin
growth rate post give current valu averag three valuat
methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
svb leerink compani file zack factset consensu
svb leerink compani file zack factset consensu
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co azn
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
